The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical ...

The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...

SkylineDx today announced the publication of new data by Dr. Wesley Yu, et al ²., demonstrating that Merlin CP-GEP identifies ...

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder ...

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...

National Comprehensive Cancer Network publishes new guidelines for Pediatric Soft Tissue Sarcomas, focused on rhabdomyosarcoma. PLYMOUTH MEETING, Pa., Feb. 17, 2026 /PRNewswire/ -- The National ...

William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

PLYMOUTH MEETING, PA [February 17, 2026] — The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft ...